BRPI0608334A2 - uso de uma formulação de clobetasol em lìquido pulverizado para o tratamento de psorìase - Google Patents

uso de uma formulação de clobetasol em lìquido pulverizado para o tratamento de psorìase

Info

Publication number
BRPI0608334A2
BRPI0608334A2 BRPI0608334-0A BRPI0608334A BRPI0608334A2 BR PI0608334 A2 BRPI0608334 A2 BR PI0608334A2 BR PI0608334 A BRPI0608334 A BR PI0608334A BR PI0608334 A2 BRPI0608334 A2 BR PI0608334A2
Authority
BR
Brazil
Prior art keywords
psoriasis
treatment
clobetasol
powdered
formulation
Prior art date
Application number
BRPI0608334-0A
Other languages
English (en)
Inventor
Gordon J Dow
Daniel M Stewart
Original Assignee
Dow Pharmaceutical Sciences
Dermatologix Partners Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Pharmaceutical Sciences, Dermatologix Partners Inc filed Critical Dow Pharmaceutical Sciences
Publication of BRPI0608334A2 publication Critical patent/BRPI0608334A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USO DE UMA FORMULAçãO DE CLOBETASOL EM LìQUIDO PULVERIZADO PARA O TRATAMENTO DE PSORIASE. A presente invenção provê um uso de uma composição farmacêutica contendo uma quantidade efetiva de propionato de clobetasol, uma composição farmacêutica preferida contendo propionato de clobetasol, álcool etílico, miristato de isopropila e agente tensoativo aniónico para a preparação de um medicamento, pulverizado sobre a pele afligida com psoriase diariamente por pelo menos quatro semanas, para o tratamento de psoriase.
BRPI0608334-0A 2005-04-25 2006-04-20 uso de uma formulação de clobetasol em lìquido pulverizado para o tratamento de psorìase BRPI0608334A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67494605P 2005-04-25 2005-04-25
PCT/US2006/014903 WO2006115987A2 (en) 2005-04-25 2006-04-20 Use of a clobetasol spray formulation to treat psoriasis

Publications (1)

Publication Number Publication Date
BRPI0608334A2 true BRPI0608334A2 (pt) 2009-12-01

Family

ID=37215257

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608334-0A BRPI0608334A2 (pt) 2005-04-25 2006-04-20 uso de uma formulação de clobetasol em lìquido pulverizado para o tratamento de psorìase

Country Status (18)

Country Link
US (2) US20060239929A1 (pt)
EP (1) EP1885373B1 (pt)
JP (1) JP2008539236A (pt)
KR (2) KR20080047312A (pt)
CN (1) CN101208096A (pt)
AU (1) AU2006241285B2 (pt)
BR (1) BRPI0608334A2 (pt)
CA (1) CA2607434A1 (pt)
DK (1) DK1885373T3 (pt)
ES (1) ES2539634T3 (pt)
HU (1) HUE025462T2 (pt)
MX (1) MX2007013230A (pt)
PL (1) PL1885373T3 (pt)
PT (1) PT1885373E (pt)
RU (1) RU2397769C2 (pt)
SI (1) SI1885373T1 (pt)
WO (1) WO2006115987A2 (pt)
ZA (1) ZA200709327B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129707A1 (en) * 2009-05-05 2010-11-11 Amgen Inc. Etanercept in combination with glucocorticoids for use in treating psoriasis
JP5833007B2 (ja) 2009-08-31 2015-12-16 ドクター・レディーズ・ラボラトリーズ・リミテッド ステロイドを含む局所製剤
US10080760B2 (en) * 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
US9789123B2 (en) 2010-10-21 2017-10-17 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment of psoriasis
US8992994B2 (en) 2010-10-21 2015-03-31 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment psoriasis
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US20160184431A1 (en) * 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
ES2857602T3 (es) 2014-03-11 2021-09-29 Promius Pharma Llc Composiciones tópicas de corticosteroides
WO2017037663A1 (en) 2015-09-02 2017-03-09 Cadila Healthcare Limited Topical compositions comprising corticosteroids
KR102399484B1 (ko) 2015-09-15 2022-05-17 주식회사 엘지생활건강 건선 치료제 전달을 위한 용해성 미세바늘 패치
KR102631435B1 (ko) 2016-06-10 2024-01-29 주식회사 엘지생활건강 타박상 치료제 전달을 위한 용해성 미세바늘 패치
US20210069214A1 (en) * 2019-09-06 2021-03-11 Encore Dermatology, Inc. Topical compositions comprising a corticosteroid for the treatment of psoriasis in pediatric patients

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972920A (en) * 1998-02-12 1999-10-26 Dermalogix Partners, Inc. Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
US5990100A (en) * 1998-03-24 1999-11-23 Panda Pharmaceuticals, L.L.C. Composition and method for treatment of psoriasis
US5886038A (en) * 1998-03-24 1999-03-23 Panda Pharmaceuticals, L.L.C. Composition and method for treatment of psoriasis
FR2761600B1 (fr) * 1998-06-19 2000-03-31 Oreal Composition moussante pour le lavage et le traitement des cheveux et/ou du cuir chevelu a base d'un principe actif, d'un tensioactif anionique, d'un tensioactif amphotere et d'un agent propenetrant
US6579512B2 (en) * 2001-06-15 2003-06-17 Crutchfield, Iii Charles E. Topical steroid spray

Also Published As

Publication number Publication date
CA2607434A1 (en) 2006-11-02
JP2008539236A (ja) 2008-11-13
KR20080047312A (ko) 2008-05-28
EP1885373A4 (en) 2010-08-18
WO2006115987A3 (en) 2006-12-14
WO2006115987A8 (en) 2008-10-16
RU2007143420A (ru) 2009-06-10
SI1885373T1 (sl) 2016-03-31
HUE025462T2 (en) 2016-02-29
PL1885373T3 (pl) 2015-12-31
EP1885373A2 (en) 2008-02-13
MX2007013230A (es) 2008-04-17
ZA200709327B (en) 2009-01-28
EP1885373B1 (en) 2015-05-20
ES2539634T3 (es) 2015-07-02
KR20110108426A (ko) 2011-10-05
AU2006241285B2 (en) 2011-04-14
AU2006241285A1 (en) 2006-11-02
RU2397769C2 (ru) 2010-08-27
US20060239929A1 (en) 2006-10-26
DK1885373T3 (en) 2015-08-10
PT1885373E (pt) 2015-09-10
US20140148426A1 (en) 2014-05-29
CN101208096A (zh) 2008-06-25
WO2006115987A2 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
BRPI0608334A2 (pt) uso de uma formulação de clobetasol em lìquido pulverizado para o tratamento de psorìase
BR0314763A (pt) Tratamento de infecções fúngicas
ATE429947T1 (de) Vorrichtung zur topischen verabreichung
MY149623A (en) Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation
WO2007067520A3 (en) Lipid-based compositions of antiinfectives for treating pulmonary infections
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
BR112012029653A2 (pt) formulação tópica para um inibidor jak
GT199900203A (es) Composiciones de celecoxib.
BRPI0407181A (pt) Formulação farmacêutica
CL2008002720A1 (es) Composicion farmaceutica transdermica para nebulizar, sin alcohol, que comprende uno o mas farmacos, los potenciadores de la penetracion transdermica eteres de dietilenglicol o filtros solares de ester, y liquidos no volatiles; dispositivo de dosificacion de nebulizacion medida que la comprende; metodo de fabricacion; y su uso.
GT199900197A (es) Formulaciones antiparasitarias.
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
UY30762A1 (es) Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2(dimetilamino) etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol
MXPA05010196A (es) Nuevas formulaciones y su uso.
WO2007133751A3 (en) Base-stabilized polyorthoester formulations
BR112023001283A2 (pt) Composição farmacêutica tópica; método para tratar uma doença, distúrbio ou afecção inflamatória de pele em um indivíduo que necessita do mesmo; e método para intensificar a penetração em pele em um indivíduo de uma formulação farmacêutica tópica
CL2004001012A1 (es) Compuestos derivados de macrolidos de 14 o 15 miembros, sustituidos en posicion 4"; procedimiento para su preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de infecciones microbianas sistemicas o topica
BRPI0411702B8 (pt) uso de ácido hialurônico para preparar composições para o tratamento de aftas da cavidade oral
NO20073575L (no) Farmasoytiske sammensetninger for behandling av cellulitt
BRPI0511209A (pt) composição farmacêutica e uso de uma associação de propionato de clobetasol e de calcitriol
BRPI0412453A (pt) uso do ácido ascórbico ou um sal fisiologicamente aceitável do mesmo
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
CL2004001010A1 (es) Compuestos derivados de macrolidos de 14 o 15 miembros, sustituidos en posicion 4"; procedimiento para su preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de infecciones microbianas sistemicas o topica
CL2004001007A1 (es) Compuestos derivados de macrolitos de 14 o 15 miembros, sustituidos en posicion 4"; procedimiento para su preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de infecciones microbianas sistemicas o topica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL